CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer

NCT03721757 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Squamous Cell Carcinoma of the Oral Cavity

Interventions

BIOLOGICAL: Nivolumab, Surgery, Radiotherapy
BIOLOGICAL: Nivolumab, Surgery, Chemoradiotherapy

Sponsor

The Clatterbridge Cancer Centre NHS Foundation Trust

Collaborators

[object Object]
[object Object]